Insider transactions

EDGAR

Biohaven Ltd.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–30 of 30

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-09-15 Filed 2026-09-17Gentile Kimberly Officer: SVP, Clinical Operations
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to buy) — underlying Common Shares (1,000) — exercise price 12.34
Acquired (A)1,0000—1,000Indirect (I) By SonNo
F1, F2
  • F1 The shares underlying this option vest in four equal installments on September 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's son's continuous service with the Issuer at each vesting date.
  • F2 Represents a stock option granted to the Reporting Person's son in connection with the commencement of his employment with the Issuer. The Reporting Person disclaims beneficial ownership of all securities held by her son, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Open filing 0001704186-26-000006 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-30Mehta Kishan Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to buy) — underlying Common Shares (68,693) — exercise price 9.61
Acquired (A)68,6930—68,693Direct (D) No
F1
  • F1 The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Open filing 0001850520-26-000005 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-30Heffernan Michael Thomas Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to buy) — underlying Common Shares (68,693) — exercise price 9.61
Acquired (A)68,6930—68,693Direct (D) No
F1
  • F1 The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Open filing 0001448914-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-30HUGIN ROBERT J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to buy) — underlying Common Shares (68,693) — exercise price 9.61
Acquired (A)68,6930—68,693Direct (D) No
F1
  • F1 The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Open filing 0001232505-26-000003 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-30Antonijevic Irina Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to buy) — underlying Common Shares (68,693) — exercise price 9.61
Acquired (A)68,6930—68,693Direct (D) No
F1
  • F1 The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Open filing 0001926476-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-30GREGORY JULIA P Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to buy) — underlying Common Shares (68,693) — exercise price 9.61
Acquired (A)68,6930—68,693Direct (D) No
F1
  • F1 The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Open filing 0001226675-26-000002 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-30Bailey Gregory Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to buy) — underlying Common Shares (68,693) — exercise price 9.61
Acquired (A)68,6930—68,693Direct (D) No
F1
  • F1 The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Open filing 0001329505-26-000005 Read from the filing’s XML Dispute this row
2026-04-28 Filed 2026-04-30CHILDS JOHN W Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to buy) — underlying Common Shares (68,693) — exercise price 9.61
Acquired (A)68,6930—68,693Direct (D) No
F1
  • F1 The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Open filing 0001027035-26-000008 Read from the filing’s XML Dispute this row
2026-03-17 Filed 2026-03-19Mehta Kishan Director
G

Bona fide gift

Common Shares
Disposed (D)17,3420—5,320Direct (D) No— Open filing 0001850520-26-000003 Read from the filing’s XML Dispute this row
2026-03-17 Filed 2026-03-19Mehta Kishan Director
G

Bona fide gift

Common Shares
Acquired (A)17,3420—17,342Indirect (I) By Kishen Mehta 21 Family Irrevocable TrustNo
F1
  • F1 These Common Shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse and the spouse's sibling are co-trustees of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Open filing 0001850520-26-000003 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Car Bruce Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to buy) — underlying Common Shares (175,000) — exercise price 11.52
Acquired (A)175,0000—175,000Direct (D) No
F1
  • F1 The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date.
Open filing 0001798876-26-000004 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Gentile Kimberly Officer: SVP, Clinical Operations
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to buy) — underlying Common Shares (175,000) — exercise price 11.52
Acquired (A)175,0000—175,000Direct (D) No
F1
  • F1 The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date.
Open filing 0001704186-26-000004 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Buten Matthew Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to buy) — underlying Common Shares (175,000) — exercise price 11.52
Acquired (A)175,0000—175,000Direct (D) No
F1
  • F1 The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date.
Open filing 0001898799-26-000004 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Coric Vlad Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to buy) — underlying Common Shares (550,000) — exercise price 11.52
Acquired (A)550,0000—550,000Direct (D) No
F1
  • F1 The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date.
Open filing 0001704317-26-000004 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Clark George C. Officer: VP, Chief Accounting Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to buy) — underlying Common Shares (50,000) — exercise price 11.52
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date.
Open filing 0001878290-26-000004 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07Car Bruce Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)4,7500—10,096Direct (D) No
F1
  • F1 This balance includes 544 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2025.
Open filing 0001798876-26-000002 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07Car Bruce Officer: Chief Scientific Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Shares
Disposed (D)2,3819.93
23,643.33

Derived: shares × price per share. Exact value 23643.33.

7,715Direct (D) No
F2, F1
  • F2 No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
  • F1 This balance includes 544 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2025.
Open filing 0001798876-26-000002 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07Car Bruce Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Share Unit Award — underlying Common Shares (4,750)
Disposed (D)4,7500—9,500Direct (D) No
F3, F4, F5
  • F3 Each restricted share unit represents the contingent right to receive one common share of the Issuer.
  • F4 The reporting person was granted 19,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date.
  • F5 Not applicable.
Open filing 0001798876-26-000002 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07Clark George C. Officer: VP, Chief Accounting Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)2,5000—68,095Direct (D) No— Open filing 0001878290-26-000002 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07Clark George C. Officer: VP, Chief Accounting Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Shares
Disposed (D)1,1179.93
11,091.81

Derived: shares × price per share. Exact value 11091.81.

66,978Direct (D) No
F1
  • F1 No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
Open filing 0001878290-26-000002 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07Clark George C. Officer: VP, Chief Accounting Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Share Unit Award — underlying Common Shares (2,500)
Disposed (D)2,5000—5,000Direct (D) No
F2, F3, F4
  • F2 Each restricted share unit represents the contingent right to receive one common share of the Issuer.
  • F3 The reporting person was granted 10,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date.
  • F4 Not applicable.
Open filing 0001878290-26-000002 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07Buten Matthew Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)4,2500—198,246Direct (D) No
F1
  • F1 This balance includes 544 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2025.
Open filing 0001898799-26-000002 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07Buten Matthew Officer: Chief Financial Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Shares
Disposed (D)2,5949.93
25,758.42

Derived: shares × price per share. Exact value 25758.42.

195,652Direct (D) No
F2, F1
  • F2 No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
  • F1 This balance includes 544 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2025.
Open filing 0001898799-26-000002 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07Buten Matthew Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Share Unit Award — underlying Common Shares (4,250)
Disposed (D)4,2500—8,500Direct (D) No
F3, F4, F5
  • F3 Each restricted share unit represents the contingent right to receive one common share of the Issuer.
  • F4 The reporting person was granted 17,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date.
  • F5 Not applicable.
Open filing 0001898799-26-000002 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07Coric Vlad Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)14,2500—1,811,398Direct (D) No— Open filing 0001704317-26-000002 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07Coric Vlad Director · Officer: Chief Executive Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Shares
Disposed (D)7,4309.93
73,779.9

Derived: shares × price per share. Exact value 73779.90.

1,803,968Direct (D) No
F1
  • F1 No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
Open filing 0001704317-26-000002 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07Coric Vlad Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Share Unit Award — underlying Common Shares (14,250)
Disposed (D)14,2500—28,500Direct (D) No
F3, F4, F5
  • F3 Each restricted share unit represents the contingent right to receive one common share of the Issuer.
  • F4 The reporting person was granted 57,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date.
  • F5 Not applicable.
Open filing 0001704317-26-000002 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07Gentile Kimberly Officer: SVP, Clinical Operations
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)3,7500—101,513Direct (D) No— Open filing 0001704186-26-000002 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07Gentile Kimberly Officer: SVP, Clinical Operations
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Shares
Disposed (D)1,9569.93
19,423.08

Derived: shares × price per share. Exact value 19423.08.

99,557Direct (D) No
F1
  • F1 No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
Open filing 0001704186-26-000002 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07Gentile Kimberly Officer: SVP, Clinical Operations
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Share Unit Award — underlying Common Shares (3,750)
Disposed (D)3,7500—7,500Direct (D) No
F2, F3, F4
  • F2 Each restricted share unit represents the contingent right to receive one common share of the Issuer.
  • F3 The reporting person was granted 15,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date.
  • F4 Not applicable.
Open filing 0001704186-26-000002 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,905 filings read, the latest filed 2026-11-18. Prior quarter ending 2026-06-30: 9,170 filings read.

Showing 1–50 of 326

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
BlackRock, Inc. Partly reported under another manager12,951,180 SH172,898,253 dollarsLower by 259,405 Prior quarter: 13,210,585Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
MONTANOVA CAPITAL, LLC 10,286,937 SH137,330,609 dollarsUnchanged Prior quarter: 10,286,937Open filing 0001172661-26-005325 Filed 2026-11-16 Dispute this row
STIFEL FINANCIAL CORP Partly reported under another manager9,941,685 SH132,721,494 dollarsHigher by 520 Prior quarter: 9,941,165Open filing 0000720672-26-000017 Filed 2026-11-12 Dispute this row
Woodline Partners LP 7,660,635 SH102,269,477 dollarsHigher by 355 Prior quarter: 7,660,280Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager6,874,721 SH91,777,525 dollarsLower by 72,313 Prior quarter: 6,947,034Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
INFINITUM ASSET MANAGEMENT, LLC 6,250,000 SH83,437,500 dollarsUnchanged Prior quarter: 6,250,000Open filing 0002058093-26-000010 Filed 2026-11-16 Dispute this row
Rubric Capital Management LP 4,875,000 SH65,081,250 dollarsHigher by 3,153,507 Prior quarter: 1,721,493Open filing 0001104659-26-128244 Filed 2026-11-16 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager4,077,524 SH54,434,947 dollarsHigher by 2,599,686 Prior quarter: 1,477,838Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
AQR CAPITAL MANAGEMENT LLC Partly reported under another manager4,053,232 SH54,110,641 dollarsLower by 97,384 Prior quarter: 4,150,616Open filing 0001167557-26-000324 Filed 2026-11-16 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager3,728,221 SH49,771,750 dollarsHigher by 1,145,175 Prior quarter: 2,583,046Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
D. E. Shaw Co., Inc. Partly reported under another manager3,725,210 SH49,731,554 dollarsLower by 464,985 Prior quarter: 4,190,195Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row
ADAGE CAPITAL PARTNERS GP, L.L.C. 3,250,000 SH43,387,500 dollarsHigher by 2,250,000 Prior quarter: 1,000,000Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager2,937,515 SH39,215,826 dollarsHigher by 418,688 Prior quarter: 2,518,827Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Royalty Pharma Sub-Manager, LLC Partly reported under another manager2,936,507 SH39,202,368 dollarsUnchanged Prior quarter: 2,936,507Open filing 0002081668-26-000021 Filed 2026-11-13 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager2,891,378 SH38,609,664 dollarsLower by 431,812 Prior quarter: 3,323,190Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
FMR LLC Partly reported under another manager2,574,373 SH34,367,861 dollarsLower by 390,257 Prior quarter: 2,964,630Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
Nuveen, LLC Partly reported under another manager2,521,538 SH33,662,532 dollarsHigher by 777,204 Prior quarter: 1,744,334Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 2,502,667 SH33,410,604 dollarsHigher by 13,726 Prior quarter: 2,488,941Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
Janus Henderson Group Ltd. Partly reported under another manager2,036,196 SH27,182,871 dollarsNot in the prior quarter’s filings read Open filing 0001085146-26-000952 Filed 2026-11-16 Dispute this row
Cormorant Asset Management, LP Partly reported under another manager1,510,000 SH20,158,500 dollarsLower by 1,100,000 Prior quarter: 2,610,000Open filing 0001583977-26-000011 Filed 2026-11-16 Dispute this row
PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager1,449,608 SH19,353 dollarsLower by 7,243 Prior quarter: 1,456,851Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 1,402,311 SH18,720,852 dollarsLower by 86,498 Prior quarter: 1,488,809Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
ARS Investment Partners, LLC 1,372,668 SH18,325,118 dollarsLower by 1,517 Prior quarter: 1,374,185Open filing 0001172661-26-004872 Filed 2026-11-05 Dispute this row
Balyasny Asset Management L.P. 1,341,024 SH17,902,670 dollarsLower by 538,710 Prior quarter: 1,879,734Open filing 0001193125-26-463223 Filed 2026-11-16 Dispute this row
ALGERT GLOBAL LLC Partly reported under another manager1,291,773 SH17,245,170 dollarsHigher by 982,793 Prior quarter: 308,980Open filing 0001275218-26-000018 Filed 2026-11-17 Dispute this row
TCG Crossover Management, LLC 1,262,423 SH16,853,347 dollarsLower by 517,529 Prior quarter: 1,779,952Open filing 0001214659-26-014306 Filed 2026-11-16 Dispute this row
Capital Research Global Investors Partly reported under another manager1,199,545 SH16,013,926 dollarsUnchanged Prior quarter: 1,199,545Open filing 0001422848-26-000129 Filed 2026-11-12 Dispute this row
Opaleye Management Inc. 1,190,000 SH15,886,500 dollarsHigher by 1,112,085 Prior quarter: 77,915Open filing 0001420506-26-002880 Filed 2026-11-16 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager1,189,537 SH15,880,318 dollarsHigher by 3,326 Prior quarter: 1,186,211Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
MYDA Advisors LLC 1,150,000 SH15,352,500 dollarsUnchanged Prior quarter: 1,150,000Open filing 0001214659-26-014141 Filed 2026-11-13 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1,139,120 SH15,207,252 dollarsHigher by 29,837 Prior quarter: 1,109,283Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
TORONTO DOMINION BANK 1,118,548 SH14,932,616 dollarsHigher by 1,020,191 Prior quarter: 98,357Open filing 0002052595-26-000123 Filed 2026-11-16 Dispute this row
Logos Global Management LP 1,100,000 SH14,685,000 dollarsNot in the prior quarter’s filings read Open filing 0001172661-26-005128 Filed 2026-11-16 Dispute this row
Logos Global Management LP Option: Call 1,000,000 SH13,350,000 dollarsNot in the prior quarter’s filings read Open filing 0001172661-26-005128 Filed 2026-11-16 Dispute this row
Caption Management, LLC Option: Call 960,800 SH12,826,680 dollarsHigher by 485,800 Prior quarter: 475,000Open filing 0001706766-26-000008 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager873,217 SH11,657,462 dollarsHigher by 31,866 Prior quarter: 841,351Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
Qube Research Technologies Ltd 833,568 SH11,128,133 dollarsLower by 72,367 Prior quarter: 905,935Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row
VANGUARD FIDUCIARY TRUST CO 796,370 SH10,631,540 dollarsLower by 32,409 Prior quarter: 828,779Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Call Partly reported under another manager793,100 SH10,587,885 dollarsHigher by 135,800 Prior quarter: 657,300Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
Capricorn Fund Managers Ltd Partly reported under another manager764,801 SH10,210,093 dollarsNot in the prior quarter’s filings read Open filing 0001901361-26-000016 Filed 2026-11-03 Dispute this row
5AM Venture Management, LLC 738,972 SH9,865,276 dollarsUnchanged Prior quarter: 738,972Open filing 0001799883-26-000004 Filed 2026-11-16 Dispute this row
Erste Asset Management GmbH 737,300 SH9,798,717 dollarsUnchanged Prior quarter: 737,300Open filing 0001398344-26-019910 Filed 2026-11-12 Dispute this row
Longaeva Partners L.P. Partly reported under another manager671,576 SH8,965,540 dollarsHigher by 71,673 Prior quarter: 599,903Open filing 0001193125-26-463222 Filed 2026-11-16 Dispute this row
VOLORIDGE INVESTMENT MANAGEMENT, LLC 670,955 SH8,957,249 dollarsLower by 211,769 Prior quarter: 882,724Open filing 0001556921-26-000010 Filed 2026-11-16 Dispute this row
Sarissa Capital Management LP 582,312 SH7,773,865 dollarsUnchanged Prior quarter: 582,312Open filing 0001420506-26-002892 Filed 2026-11-16 Dispute this row
Simplify Asset Management Inc. 550,693 SH7,351,752 dollarsLower by 489,562 Prior quarter: 1,040,255Open filing 0001172661-26-004722 Filed 2026-10-27 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager545,162 SH7,342,140 dollarsHigher by 75,330 Prior quarter: 469,832Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Partly reported under another manager540,310 SH7,213,138 dollarsHigher by 539,562 Prior quarter: 748Open filing 0000861177-26-000005 Filed 2026-11-16 Dispute this row
SummitTX Capital, L.P. 532,414 SH7,107,727 dollarsNot in the prior quarter’s filings read Open filing 0002052310-26-000008 Filed 2026-11-16 Dispute this row
Pfizer Inc 505,645 SH6,568,329 dollarsUnchanged Prior quarter: 505,645Open filing 0000078003-26-000135 Filed 2026-11-12 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Jupiter Topco LLC 8,584,675 SH
  • CITADEL ADVISORS LLC 1,619,676 SH
  • Sixth Street Partners Management Company, L.P. 1,109,283 SH
  • Eversept Partners, LP 515,804 SH
  • Trexquant Investment LP 503,694 SH
  • STEMPOINT CAPITAL LP 500,000 SH
  • Point72 Asset Management, L.P. 491,918 SH
  • Aberdeen Group plc 365,519 SH
  • Affinity Asset Advisors, LLC 250,000 SH
  • NewEdge Wealth, LLC 245,670 SH
  • XTX Topco Ltd 170,163 SH
  • SPHERA FUNDS MANAGEMENT LTD. 164,437 SH
  • SG Americas Securities, LLC 101,920 SH
  • VIRGINIA RETIREMENT SYSTEMS ET Al 88,400 SH
  • Voleon Capital Management LP 74,798 SH
  • Schonfeld Strategic Advisors LLC 72,396 SH
  • Aquatic Capital Management LLC 50,585 SH
  • CAPITAL FUND MANAGEMENT S.A. 47,097 SH
  • Greenland Capital Management LP 46,000 SH
  • AXQ CAPITAL, LP 45,891 SH
  • OPTIMIZE FINANCIAL INC. 44,524 SH
  • Sound Capital Solutions LLC 44,524 SH
  • Jain Global LLC 34,858 SH
  • Greenland Capital Management LP 30,000 SH
  • INTECH INVESTMENT MANAGEMENT LLC 27,859 SH
  • Headlands Technologies LLC 26,339 SH
  • SIMPLEX TRADING, LLC 23,317 SH
  • Morgan Creek Capital Management, LLC 18,193 SH
  • OXFORD ASSET MANAGEMENT LLP 17,871 SH
  • GTS SECURITIES LLC 16,988 SH
  • Centiva Capital, LP 16,722 SH
  • MAI Capital Management 14,099 SH
  • Quantbot Technologies LP 13,132 SH
  • WADDELL ASSOCIATES, LLC 10,351 SH
  • BlueCrest Capital Management Ltd 4,000 SH
  • Pacer Advisors, Inc. 1,760 SH
  • AdvisorNet Financial, Inc 500 SH
  • Wealth Enhancement Trust Services, Inc. 369 SH
  • Aster Capital Management (DIFC) Ltd 334 SH
  • Optiver Holding B.V. 328 SH
  • Private Wealth Asset Management, LLC 200 SH
  • SHP Wealth Management 100 SH
  • Ares Financial Consulting, LLC 84 SH
  • BESSEMER GROUP INC 79 SH
  • BERTHEL, FISHER COMPANY FINANCIAL SERVICES, INC. 72 SH
  • Ameritas Advisory Services, LLC 24 SH
  • Park Place Capital Corp 19 SH
  • Stone House Investment Management, LLC 16 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
JANUS HENDERSON GROUP Ltd. Common Shares1.42,036,19709/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0001274173-26-000262 Dispute this row
Woodline Partners LP Common Shares, no par value per share5.17,660,280.0006/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0000919574-26-005259 Dispute this row
JANUS HENDERSON GROUP Ltd. Common Shares5.78,584,67606/30/2026 Filed 2026-07-08SCHEDULE 13G/AAmendment 2Open filing 0001274173-26-000170 Dispute this row
JANUS HENDERSON GROUP PLC Common Shares11.717,534,61203/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001274173-26-000140 Dispute this row
JANUS HENDERSON GROUP PLC Common Shares12.716,803,45901/30/2026 Filed 2026-02-06SCHEDULE 13G/AAmendment 1Open filing 0001274173-26-000045 Dispute this row
SUVRETTA CAPITAL MANAGEMENT, LLC Common Shares, no par value7.810,286,937.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 3Open filing 0000919574-26-000942 Dispute this row
AVERILL MASTER FUND, LTD. Common Shares, no par value6.68,800,438.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 3Open filing 0000919574-26-000942 Dispute this row
AARON COWEN Common Shares, no par value7.810,286,937.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 3Open filing 0000919574-26-000942 Dispute this row
JANUS HENDERSON GROUP PLC Common Stock6.46,772,11309/30/2025 Filed 2025-11-14SCHEDULE 13GOpen filing 0001274173-25-000271 Dispute this row
The Vanguard Group Common Stock2.712,875,19009/30/2025 Filed 2025-10-30SCHEDULE 13G/AAmendment 1Open filing 0000102909-25-000041 Dispute this row
JANUS HENDERSON GROUP PLC Common Stock4.95,053,52806/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 5Open filing 0001274173-25-000199 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,556,900 filings read, dated 2004-06-14 to 2026-11-18: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,857
2016222,642
2017222,009
2018223,345
2019216,482
2020183,193
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026262,403

Filings made before the SEC required XML are listed, not extracted.

Back to Biohaven Ltd.